We are live on ! Find out more
RPTX

Repare Therapeutics

Delisted

RPTX was delisted on the 27th of January, 2026.

71 hedge funds and large institutions have $167M invested in Repare Therapeutics in 2024 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 16 increasing their positions, 25 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

383% more call options, than puts

Call options by funds: $145K | Put options by funds: $30K

50% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 4

3% more funds holding

Funds holding: 6971 (+2)

3.28% less ownership

Funds ownership: 87.47%84.19% (-3.3%)

25% less funds holding in top 10

Funds holding in top 10: 43 (-1)

36% less repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 25

38% less capital invested

Capital invested by funds: $269M → $167M (-$102M)

Holders
71
Holders Change
+2
Holders Change %
+2.9%
% of All Funds
1.02%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.04%
New
6
Increased
16
Reduced
25
Closed
4
Calls
$145K
Puts
$30K
Net Calls
+$115K
Net Calls Change
-$172K
Name Holding Trade Value Shares
Change
Change in
Stake
HP
51
Harbourvest Partners
Massachusetts
$57.8K
Two Sigma Advisers
52
Two Sigma Advisers
New York
$55.1K +$75K +11,700 New
BHCM
53
Brevan Howard Capital Management
Jersey
$51.6K -$30.3K -4,729 -30%
CIBC World Market
54
CIBC World Market
Ontario, Canada
$49K
AAP
55
Arax Advisory Partners
Colorado
$47.1K
Group One Trading
56
Group One Trading
Illinois
$36K -$25.9K -4,041 -35%
Simplex Trading
57
Simplex Trading
Illinois
$24K -$33.8K -5,276 -50%
TRCT
58
Tower Research Capital (TRC)
New York
$18.7K +$24.2K +3,776 +1,888%
QT
59
Quantbot Technologies
New York
$9.63K -$21.1K -3,300 -62%
New York State Common Retirement Fund
60
New York State Common Retirement Fund
New York
$6.23K
National Bank of Canada
61
National Bank of Canada
Quebec, Canada
$5.75K
Wells Fargo
62
Wells Fargo
California
$5.41K -$205 -32 -3%
TWC
63
TD Waterhouse Canada
Ontario, Canada
$5.38K
FDCDDQ
64
Federation des caisses Desjardins du Quebec
Quebec, Canada
$5.22K
EC
65
EntryPoint Capital
New York
$4.73K +$6.44K +1,005 New
Qube Research & Technologies (QRT)
66
Qube Research & Technologies (QRT)
United Kingdom
$4.61K -$13.3K -2,082 -68%
Barclays
67
Barclays
United Kingdom
$2.5K
UBS Group
68
UBS Group
Switzerland
$2.44K +$3.27K +511 +7,300%
Royal Bank of Canada
69
Royal Bank of Canada
Ontario, Canada
$1K -$4.77K -744 -72%
Citigroup
70
Citigroup
New York
$160
JP Morgan Chase
71
JP Morgan Chase
New York
$19
LGM
72
Logos Global Management
California
-$4.38M -600,000 Closed
Marshall Wace
73
Marshall Wace
United Kingdom
-$196K -26,866 Closed
Lazard Asset Management
74
Lazard Asset Management
New York
-$21K -3,008 Closed
Legal & General Group
75
Legal & General Group
United Kingdom
-$5.15K -706 Closed

RPTX Hedge Fund Activity: Q1 2024 in Review

71 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Repare Therapeutics (RPTX) for Q1 2024, worth a combined $167M — down 38% from $269M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new RPTX positions and 4 closed out — a net gain of 2 holders — while 16 added to existing stakes and 25 trimmed.

The largest buyer was Opaleye Management, opening a new position worth an estimated $433K. The largest seller was Logos Global Management, exiting entirely with an estimated $4.38M sold.

  • 71 institutional investors held Repare Therapeutics (RPTX) as of Q1 2024, up from 69 in Q4 2023.
  • Funds reported $167M of Repare Therapeutics stock for Q1 2024, down 38% quarter-over-quarter.
  • 6 funds opened new Repare Therapeutics positions in Q1 2024 and 4 closed out, a net change of +2 holders.
  • The largest Repare Therapeutics buyer in Q1 2024 was Opaleye Management, an estimated $433K added.
  • The largest Repare Therapeutics seller in Q1 2024 was Logos Global Management, an estimated $4.38M sold.

Based on aggregated 13F filings for Q1 2024.